医学
溃疡性结肠炎
内科学
小RNA
结肠炎
梅德林
遗传学
基因
政治学
生物
法学
疾病
作者
Raja Atreya,Markus F. Neurath
标识
DOI:10.1016/s2468-1253(22)00249-7
摘要
In The Lancet Gastroenterology & Hepatology, Severine Vermeire and colleagues1 report the results from a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension of ABX464 (obefazimod) in patients with moderate-to-severe ulcerative colitis. Patients were randomly assigned to daily oral ABX464 25 mg (n=63), 50 mg (n=63), 100 mg (n=64), or placebo (n=64). At week 8, the modified Mayo Score (MMS) was significantly improved from baseline in all ABX464 dosage groups compared with placebo.
科研通智能强力驱动
Strongly Powered by AbleSci AI